Core Viewpoint - A class action securities lawsuit has been filed against StubHub Holdings, Inc. alleging securities fraud related to its initial public offering in September 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors who purchased StubHub common stock based on the registration statement and prospectus from the September 2025 IPO [2]. - The complaint claims that the defendants made false statements and concealed significant changes in payment timing to vendors, which adversely affected the company's free cash flow [3]. - It is alleged that these misleading statements resulted in materially inaccurate reports regarding the company's free cash flow and overall business prospects [3]. Group 2: Next Steps for Investors - Investors who suffered losses in StubHub Holdings, Inc. have until January 23, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require this [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex securities cases [5].

Core Viewpoint - A class action securities lawsuit has been filed against Coupang, Inc. alleging securities fraud related to inadequate cybersecurity protocols and failure to report a data breach [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2025, and December 16, 2025 [1]. - The complaint claims that Coupang had inadequate cybersecurity measures that allowed a former employee to access sensitive customer information for nearly six months without detection [2]. - It is alleged that the company did not report the data breach in compliance with SEC reporting rules, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the relevant time frame have until February 17, 2026, to request to be appointed as lead plaintiff [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4].

Core Viewpoint - A class action lawsuit has been filed against Varonis Systems, Inc. for alleged securities fraud and unlawful business practices [2]. Financial Performance - Varonis reported financial results for Q3 2025, with revenue missing consensus estimates and a significant 63.9% year-over-year decline in term license subscription revenues [3]. - The company has reduced its full-year Annual Recurring Revenue (ARR) guidance due to underperformance in its on-prem subscription business [3]. - On an earnings call, the CEO indicated that the on-premises subscription business is negatively impacting total company ARR growth, citing lower renewal rates and sales process issues as contributing factors [3]. Stock Market Reaction - Following the release of the disappointing financial results, Varonis's stock price fell by $30.66 per share, or 48.67%, closing at $32.34 per share on October 29, 2025 [3].

Core Viewpoint - A federal securities class action has been filed against Agilon Health, Inc. for alleged securities fraud during the class period from February 6, 2025, to August 4, 2025, with a deadline for investors to seek lead plaintiff status by March 2, 2026 [1][2]. Group 1: Legal Action - The complaint alleges that Agilon and certain officers and/or directors engaged in securities fraud or other unlawful business practices [2]. - Investors who purchased Agilon shares during the specified class period are eligible to join the class action [1]. Group 2: Market Reaction - Following the announcements made on August 4, 2025, Agilon's stock price fell by $0.94 per share, representing a 51.52% decline, closing at $0.88 on August 5, 2025 [3]. Group 3: Company Leadership and Financial Update - Steven Sell has stepped down as President, CEO, and Board Director of Agilon [7]. - The company reported its Q2 2025 results, with the Executive Chair noting that industry headwinds were "more acute than previously expected" [7]. - Agilon has suspended its full-year 2025 financial guidance due to these challenges [7].

Core Viewpoint - A class action securities lawsuit has been filed against Coupang, Inc. alleging securities fraud related to inadequate cybersecurity protocols and failure to report a data breach [1][2]. Group 1: Lawsuit Details - The lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2025, and December 16, 2025 [1]. - The complaint claims that Coupang had inadequate cybersecurity measures that allowed a former employee to access sensitive customer information for nearly six months without detection [2]. - It is alleged that the company did not report the data breach in compliance with SEC reporting rules, leading to materially false and misleading public statements [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until February 17, 2026, to request appointment as lead plaintiff [3]. - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3]. Group 3: Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and is recognized as one of the top securities litigation firms in the U.S. [4]. - The firm has over 70 employees dedicated to serving clients in complex securities litigation [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Zenas BioPharma, Inc. following a significant drop in stock price after the announcement of Phase 3 trial results for obexelimab [1][3]. Group 1: Company Overview - Zenas BioPharma, Inc. (NASDAQ: ZBIO) is currently under investigation for possible securities fraud [1]. - The company recently announced results from the Phase 3 INDIGO trial of obexelimab for Immunoglobulin G4-Related Disease (IgG4-RD) [3]. Group 2: Financial Impact - Following the announcement of the trial results, Zenas's stock price decreased by $17.89 per share, representing a decline of 51.86%, closing at $16.61 per share on January 5, 2026 [3]. Group 3: Legal Context - Pomerantz LLP is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4].

Core Viewpoint - Hagens Berman is reminding investors in Stride, Inc. (NYSE: LRN) about the deadline of January 12, 2026, to apply for lead plaintiff status in a securities class action lawsuit related to significant losses incurred by investors due to alleged fraudulent activities [1][9]. Group 1: Allegations of Fraud - The lawsuit claims that Stride, Inc. engaged in two fraudulent schemes: inflating enrollment figures through "Ghost Students" and a significant technology platform failure, which collectively caused a 54% stock crash in one day, resulting in billions in market capitalization loss [2][4]. - The complaint alleges that Stride and its executives misled investors regarding core business metrics and operational stability, with the CEO acknowledging that the platform upgrade failure led to a "poor customer experience," contradicting previous claims of strong growth [3][4]. Group 2: Specific Allegations - **Enrollment Fraud**: Stride allegedly used unlawful practices by retaining "Ghost Students" to artificially inflate enrollment metrics, leading to an 11% stock drop upon partial disclosure of these facts [6]. - **Technology Catastrophe**: The company reportedly failed to disclose severe issues with a critical platform upgrade that blocked access for approximately 10,000 to 15,000 students, resulting in a forecasted sales growth decline to 5% from a historical 19%, which contributed to the 54% stock crash [7][8]. Group 3: Legal Proceedings and Investor Impact - The lawsuit seeks to recover losses for investors who purchased LRN securities during the Class Period from October 22, 2024, to October 28, 2025, holding Stride and its executives accountable for alleged misrepresentations [9]. - Hagens Berman is actively advising affected investors and emphasizes the importance of contacting them before the lead plaintiff deadline [10][11].

Core Viewpoint - A securities fraud lawsuit has been filed against agilon health, inc. following a significant drop in its stock price due to the resignation of its CEO and the withdrawal of its financial guidance for 2025 [1][2]. Group 1: Company Developments - Shares of agilon health, Inc. fell more than 25% in after-hours trading on August 4, 2025, after the announcement of CEO Steven Sell's immediate resignation and the withdrawal of the full-year 2025 financial guidance [2]. - The company cited unexpected medical cost pressures and downward adjustments to prior revenue estimates as reasons for these actions [2]. Group 2: Allegations in the Lawsuit - The complaint alleges that agilon recklessly issued guidance for 2025 that they knew or should have known was unattainable due to material industry headwinds [3]. - It is claimed that agilon materially overstated the immediate positive financial impact from strategic actions taken to reduce risk, leading to materially false and/or misleading statements about the company's business and prospects [3]. Group 3: Investor Information - Investors who purchased agilon health, inc. common stock between February 26, 2025, and August 4, 2025, and have experienced a loss may be eligible to participate in the lawsuit [4]. - The deadline to seek appointment as lead plaintiff is March 2, 2026, and a class has not yet been certified [5]. Group 4: Whistleblower Information - Individuals with non-public information about agilon health, inc. are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, potentially receiving rewards of up to 30% of any successful recovery [6]. Group 5: Legal Representation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Inspire Medical and its executives assured investors of the company's "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - The class period for the lawsuit includes investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2]. - The lead plaintiff deadline for the lawsuit is January 5, 2026, urging affected investors to contact the law firm Hagens Berman [3]. Group 2: Allegations of Concealment - Allegations include failures in Medicare claims processing software that delayed the rollout of the Inspire V device, impacting revenue generation [4]. - An excess inventory of the older Inspire IV device created a demand issue for the new Inspire V, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical operational issues, particularly the Medicare claims software failure and the inventory surplus of the Inspire IV device [5]. - The firm asserts that the stock collapse was due to management prioritizing a narrative of a seamless transition over the actual operational challenges [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Company Overview - Inspire Medical Systems, Inc. develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Lawsuit Details - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Inspire stock, with the case pending in the U.S. District Court for the District of Minnesota [3]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V was facing an "elongated timeframe," leading to a reduction in 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8]. Reasons for Stock Drop - The delays in the rollout of Inspire V were attributed to inadequate preparation for clinicians and payors, resulting in significant adoption delays and weak demand due to customers having excess inventory of older devices [6][7].